Von Hippel-Lindau disease: clinical and molecular perspectives (Q34305239)

1 August 2017

1 reference

title

Von Hippel-Lindau disease: clinical and molecular perspectives (English)

1 reference

von Hippel-Lindau disease

1 August 2017

1 reference

S C Clifford

1

1 reference

PubMed ID

11447766

1 August 2017

E R Maher

series ordinal

2

1 reference

1 August 2017

1 January 2001

1 reference

Advances in Cancer Research

1 August 2017

1 reference

1 August 2017

82

1 reference

1 August 2017

85-105

1 reference

Software and database for the analysis of mutations in the VHL gene

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Inhibition of transcription elongation by the VHL tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Von Hippel-Lindau disease: a genetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Isolation and characterization of the full-length 3' untranslated region of the human von Hippel-Lindau tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Familial non-VHL non-papillary clear-cell renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Risk of multisystem disease in isolated ocular angioma (haemangioblastoma)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2982003-0

7 January 2021

10.1016/S0065-230X(01)82003-0

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11447766